Cambridge, Mass. — eGenesis has appointed Glenn S. Vraniak as chief financial officer and promoted Jennifer Bergheiser to chief commercial officer as the biotechnology company advances its engineered-organ transplantation programs.
The leadership changes come as eGenesis moves forward with clinical studies involving EGEN-2784 for kidney failure and a separate program for acute-on-chronic liver failure.
“eGenesis is entering a pivotal stage in our evolution as we prepare to advance our programs through clinical development and lay the foundation for future commercialization,” said Mike Curtis, Ph.D., Chief Executive Officer, eGenesis. “Glenn brings deep expertise and proven leadership across finance, capital formation, and business development and we are thrilled to have him join the team to help drive the next phase of growth for the company.”
Vraniak has more than 20 years of executive leadership experience in biotechnology, medical technology and specialty pharmaceuticals. He most recently served as chief financial officer of Inversago Pharma, where he supported the company’s growth strategy, financing activities and acquisition by Novo Nordisk in a transaction valued at approximately $1.1 billion.
He previously served as CFO of Evaxion Biotech, Valeo Detection Systems and electroCore. Vraniak also served on the board of Apollomics Inc. and chaired its audit committee.
During his career, Vraniak has helped raise hundreds of millions of dollars in private and public capital, led initial public offering preparations and supported strategic transactions. At Inversago, he completed a $70 million Series C financing and helped negotiate the company’s acquisition.
“eGenesis has built one of the most innovative platforms in biotechnology and is addressing one of the largest unmet needs in medicine,” said Vraniak. “The opportunity to revolutionize the treatment of organ failure and potentially save countless lives is incredibly compelling. I look forward to working alongside this talented team as we advance our clinical programs, strengthen our operational capabilities and position the company for long-term success.”
Bergheiser has served as eGenesis’ chief business officer since 2022. She has more than 25 years of experience across biopharmaceuticals, biotechnology, private equity and strategy consulting, including leadership roles in product strategy, commercialization planning, business development and market access.
Her experience includes early brand and commercial strategy for biologic therapies such as Stelara.
In her new role, Bergheiser will lead product and market development for EGEN-2784 and the company’s broader pipeline. She will oversee product management, market access, government affairs, patient advocacy and channel strategy as eGenesis prepares for potential commercialization.
“Jen has a proven track record of building and scaling high-performing teams at eGenesis,” said Curtis. “She has led key functions across G&A while driving our new product planning efforts over the past several years. We look forward to her continued leadership as we begin laying the foundation for commercialization.”
“The shortage of organs for transplant is a public health crisis, exacting a staggering toll on patients, families, clinicians and healthcare systems,” said Bergheiser. “The opportunity to lead eGenesis’ efforts in preparing the market, and our game-changing product portfolio, for commercialization is unmatched. I look forward to partnering with stakeholders across the healthcare landscape to help define a new category of medicine and enable access to a novel and life-saving treatment option for people whose lives have been put on hold by organ failure.”
